Tumor-derived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine

Journal of Immunology

Volumn 170, Issue 7, 2003, Pages 3806-3811

  Kao, John Y ^a   Gong, Yusong ^a   Chen, Chuan Min ^a   Zheng, Qiong Duan ^a   Chen, Jian Jun ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CELL ACTIVITY; CELL FUSION; COLON CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

EID: 0037379315     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.7.3806     Document Type: Article

References (47)

1. Kugler, A., G. Stuhler, P. Walden, G. Zoller, A. Zobywalski, P. Brossart, U. Trefzer, S. Ullrich, C. A. Muller, V. Becker, et al. 2000. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6:332.
2. Tjoa, B. A., S. J. Simmons. A. Elgamal, M. Rogers, H. Ragde, G. M. Kenny, M. J. Troychak, A. L. Boynton, and G. P. Murphy. 1999. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40:125.
3. Murphy, G. P., B. A. Tjoa, S. J. Simmons, H. Ragde, M. Rogers, A. Elgamal, G. M. Kenny, M. J. Troychak, M. L. Salgaller, and A. L. Boynton. 1999. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39:54.
4. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
5. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
6. Ohshima, Y., and G. Delespesse. 1997. T cell-derived IL-4 and dendritic cellderived IL-12 regulate the lymphokine-producing phenotype of alloantigenprimed naive human CD4 T cells. J. Immunol. 158:629.
7. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, and M. J. Bevan. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270.
8. Shen, Z., G. Reznikoff, G. Dranoff, and K. L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158:2723.
9. Nair, S., F. Zhou, R. Reddy, L. Huang, and B. T. Rouse. 1992. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J. Exp. Med. 175:609.
10. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
11. Walden. P. 2000. Hybrid cell vaccination for cancer immunotherapy. Adv. Exp. Med. Biol. 465:347.
12. + T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 101:316.
13. Kuppner, M. C., Y. Sawamura, M. F. Hamou, and N. de Tribolet. 1990. Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes. J. Neurosurg. 72:619.
14. Torre-Amione, G., R. D. Beauchamp, H. Koeppen, B. H. Park, H. Schreiber, H. L. Moses, and D. A. Rowley. 1990. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87:1486.
15. Maxwell, M., T. Galanopoulos, J. Neville-Golden, and H. N. Antoniades. 1992. Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J. Neurosurg. 76:799.
16. Bomstein, Y., R. Ophir, H. Harshemes, and S. Ben-Efraim. 1993. Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defence. Anticancer Res. 13:2125.
17. Daughaday, W. H., and T. F. Deuel. 1991. Tumor secretion of growth factors. Endocrinol. Metab. Clin. North Am. 20:539.
18. Rook, A. H., J. H. Kehrl, L. M. Wakefield, A. B. Roberts, M. B. Sporn, D. B. Burlington, H. C. Lane, and A. S. Fauci. 1986. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136:3916.
19. + T cells. J. Immunol. 155:609.
20. Hsieh, C. L., D. S. Chen, and L. H. Hwang. 2000. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum. Gene Ther. 11:681.
21. Strobl, H., and W. Knapp. 1999. TGF-β1 regulation of dendritic cells. Microbes Infect. 1:1283.
22. Riedl, E., H. Strobl, O. Majdic, and W. Knapp. 1997. TGF-β1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J. Immunol. 158:1591.
23. Yamaguchi, Y., H. Tsumura, M. Miwa, and K. Inaba. 1997. Contrasting effects of TGF-β 1 and TNF-α on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15:144.
24. Sato, K., H. Kawasaki, H. Nagayama, M. Enomoto, C. Morimoto, K. Tadokoro, T. Juji, and T. A. Takahashi. 2000. TGF-β1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 164:2285.
25. + T and NK cells. J. Exp. Med. 180:1937.
26. + T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-β: implications for dendritic cell immunization against cancer. Clin. Immunol. 102:96.
27. Fearon, E. R., and B. Vogelstein. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759.
28. Wang, J., S. Saffold, X. Cao, J. Krauss, and W. Chen. 1998. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161:5516.
29. Fields, R. C., J. J. Osterholzer, J. A. Fuller. E. K. Thomas, P. J. Geraghty, and J. J. Mule. 1998. Comparative analysis of murine dendritic cells derived from spleen and bone marrow. J. Immunother. 21:323.
30. Holmes, L. M., J. Li, R. P. Sticca, T. E. Wagner, and Y. Wei. 2001. A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dentritomas. J. Immunother. 24:122.
31. Cohen, P. J., P. A. Cohen, S. A. Rosenberg, S. I. Katz, and J. J. Mule. 1994. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur. J. Immunol. 24:315.
32. Tzai, T. S., A. L. Shiau, C. S. Lin, C. L. Wu, and J. S. Lin. 1997. Modulation of the immunostimulating effect of autologous tumor vaccine by anti-TGF-β antibody and interferon-α on murine MBT-2 bladder cancer. Anticancer Res. 17:1073.
33. Fischer, J. R., H. Darjes, H. Lahm, M. Schindel, P. Drings, and P. H. Krammer. 1994. Constitutive secretion of bioactive transforming growth factor β1 by small cell lung cancer cell lines. Eur. J. Cancer 30A:2125.
34. Li, J., L. M. Holmes, K. J. Franek, K. E. Burgin, T. E. Wagner, and Y. Wei. 2001. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol. Immunother. 50:456.
35. Lindner, M., and V. Schirrmacher. 2002. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur. J. Clin. Invest. 32:207.
36. Homma, S., G. Toda, J. Gong, D. Kufe, and T. Ohno. 2001. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. Gastroenterol. 36:764.
37. Wan, Y., J. Bramson, A. Pilon, Q. Zhu, and J. Gauldie. 2000. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res. 60:3247.
38. Chen, Y., P. Emtage, Q. Zhu, R. Foley, W. Muller, M. Hitt, J. Gauldie, and Y. Wan. 2001. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther. 8:316.
39. Hellstrom, I., J. A. Ledbetter, N. Scholler, Y. Yang, Z. Ye, G. Goodman, J. Pullman, M. Hayden-Ledbetter, and K. E. Hellstrom. 2001. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc. Natl. Acad. Sci. USA 98:6783.
40. Furumoto, K., S. Arii, S. Yamasaki, M. Mizumoto, A. Mori, N. Inoue, N. Isobe, and M. Imamura. 2000. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int. J. Cancer 87:665.
41. Ju, D. W., Q. Tao, G. Lou, M. Bai, L. He, Y. Yang, and X. Cao. 2001. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res. 61:3735.
42. Kikuchi, T., N. Miyazawa, M. A. Moore, and R. G. Crystal. 2000. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res. 60:6391.
43. + T cells. Nat. Med. 6:1154.
44. Kikuchi, T., M. A. Moore, and R. G. Crystal. 2000. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96:91.
45. Shimizu, K., R. C. Fields, B. G. Redman, M. Giedlin, and J. J. Mule. 2000. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2. Cancer J. Sci. Am. 6(Suppl. 1):S67.
46. Zhang, W., X. Cao, and X. Huang. 1997. In vivo induction of antitumor immune response by tumor cells fused with GM-CSF gene-modified dendritic cells. Zhonghua Yi Xue Za Zhi 77:39.
47. Gorelik, L., and R. A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:1118.